Loading stock data…
GMAB
$27.04+0.59 (+2.23%)
Market ClosedLast close May 4
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $27.04. The stock is currently 24% below its 52-week high of $35.43, remaining 6.1% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why GMAB maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$27.04
Potential Upside
26.5%
Whystock Fair Value$34.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$37.45+38.5%
Range$30.50 – $48.00
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.04%
Volume
Today's trading volume
1.19M
Recent News
Genmab (GMAB) Rated Outperform on Oncology Pipeline
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical triggers anticipated in 2026, the firm sees the current price dip following a loss in a confirmatory […]
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Genmab A/S is among the best biotech stocks. TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and set a price target of $30.50. The upgrade reflected expectations of […]
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence
Investing.com -- Goldman Sachs upgraded Genmab to Buy from Neutral on Wednesday, citing growing confidence in three key pipeline assets that the bank believes could de-risk more than $5 billion in peak sales potential over the remainder of 2026.
Genmab (CPSE:GMAB) Valuation Check After Mixed Recent Share Performance
Genmab share performance sets the stage Genmab (CPSE:GMAB) has drawn investor attention after a month return of about 10%, alongside a past 3 months decline near 10% and a near 40% total return over the past year. See our latest analysis for Genmab. That mix of a 10.2% 1 month share price return, a 9.7% 3 month share price decline, and a 39.7% 1 year total shareholder return suggests near term enthusiasm building on a stronger longer term recovery in investor sentiment. If you are weighing...